Hims & Hers (HIMS) has taken a beating, with the inventory down roughly 70% from its $70 peak and now buying and selling beneath $21 per share.
However the story’s altering.
After the corporate’s Novo Nordisk (NVO) deal and the top of the FDA scarcity, Hims is shifting to a broader mixture of branded, FDA-approved GLP-1s whereas pulling again from compounded provide.
It is a shift in how the enterprise operates. The query now could be whether or not HIMS can construct a worthwhile, sturdy mannequin.
In easy phrases, Hims & Hers is a web-based well being care platform that helps individuals get prescriptions and coverings with out visiting a physician’s workplace.
The corporate makes cash by connecting sufferers with licensed suppliers and promoting subscription-based remedies throughout weight reduction, dermatology, psychological well being, and extra.
The enterprise’s aggressive benefit comes from its model, digital expertise, and rising function as a distribution layer between sufferers and drugmakers, particularly because it expands partnerships with corporations like Novo Nordisk.
The long-term alternative continues to be significant if Hims can scale this mannequin and preserve robust unit economics.
Novo deal resets weight-loss provide mannequin
Hims & Hers’ collaboration with Novo Nordisk on March 9 marked its clearest transfer away from compounded semaglutide and towards branded, FDA-approved weight-loss medicine.
The shift got here after the FDA stated the semaglutide scarcity was over, eradicating the important thing regulatory opening that had supported broad compounded provide.
Extra Development Shares:
- Morgan Stanley units jaw-dropping Micron value goal after occasion
- Nvidia’s China chip drawback isn’t what most traders assume
- Quantum Computing makes $110 million transfer no person noticed coming
The corporate noticed “tremendous growth opportunities in the U.S. with the expanding assortment of branded GLP-1 medications,” CEO Andrew Dudum stated, pointing to a mannequin the place drugmakers and digital well being platforms may work collectively to scale distribution.
Then, in an replace on Thursday, March 26, Hims stated it “will no longer actively market compounded GLP-1 offerings on its platform or in its marketing,” and can as an alternative information most sufferers towards branded remedies, whereas preserving compounded choices out there solely in restricted, clinically essential instances.
This replace highlights a broader technique. Hims plans to “provide GLP-1 customers with access to a broad assortment of FDA-approved medications” by means of companions equivalent to Novo Nordisk.
The transfer offers Hims a extra sturdy and compliant provide path for a class that fueled its breakout development, however it possible comes with decrease margins and higher dependence on third-party drugmakers.
Breakout outcomes meet slower 2026 development
For fiscal yr 2025, Hims & Hers reported roughly $2.35 billion in income, up 59% from a yr earlier, together with $318 million in adjusted EBITDA and $128 million in web earnings, in keeping with its Feb. 23 earnings launch.
However that development got here from a really totally different mannequin than the one beneath which Hims operates as we speak.
Steering already displays a few of that transition. Analysts’ midpoint income estimate for fiscal 2026 income is about $2.73 billion, implying roughly 16.4% year-over-year development. This is able to be a pointy slowdown from 2025’s 59% development.
On the similar time, gross margins are projected to say no from about 74% in 2025 to roughly 72% in 2026, reflecting the shift away from higher-margin compounded merchandise towards branded medicine with decrease take charges.
Tatsiana Volkava by way of Getty Photographs
Working profitability can also be anticipated to indicate near-term strain. EBITDA margins are anticipated to fall from 13.5% in 2025 to 12.0% in 2026, with EBITDA development slowing to only 2.7% yr over yr.
Wanting additional out, analysts count on margins to develop once more because the platform scales, with EBITDA margins anticipated to succeed in 12.8% in 2027 and 14.3% by 2028.
Margins could take successful within the quick time period earlier than transferring increased over the long run.
What may push HIMS increased
Wall Avenue analysts at the moment have a median value goal of simply over $24/share for HIMS, implying the inventory may have 16.6% upside as we speak.
Moreover, the inventory trades at traditionally low cost multiples. There are numerous components that might drive long-term upside for the inventory.
- Extra sturdy weight-loss development from branded GLP-1 provide
- Larger subscriber lifetime worth from cross-selling throughout weight reduction, dermatology, and psychological well being
- Working leverage, as mounted advertising and marketing and platform prices scale with a bigger person base
- Improved client belief and conversion charges from FDA-approved remedies
- New drugmaker partnerships that develop therapy choices past Novo Nordisk
- Continued robust telehealth demand throughout core classes
- Potential worldwide enlargement that will increase the full addressable market
What may weigh on HIMS
- Decrease gross margins as the combo shifts from compounded to branded GLP-1 medicine
- Slower income development in 2026 could strain the inventory’s valuation
- Excessive buyer acquisition prices that restrict profitability if advertising and marketing effectivity declines
- Elevated regulatory and authorized scrutiny round GLP-1 practices
- Execution danger in transitioning sufferers to new provide channels
- Dependence on third-party suppliers like Novo Nordisk
- Intensifying competitors throughout telehealth and weight-loss platforms
- Potential harm to model belief from ongoing controversy or adverse headlines
Key takeaway for traders
The important thing query now could be whether or not HIMS can drive working leverage from scaling its mannequin.
Traders ought to watch margin developments, subscriber development, and execution on branded GLP-1 provide within the coming quarters.
Associated: Novo and Lilly shift GLP-1 technique overseas: US could also be subsequent
